Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma

Shiro Suzuki, Toshiaki Yoshikawa, Tomoya Hirosawa, Kiyosumi Shibata, Fumitaka Kikkawa, Yoshiki Akatsuka, Tetsuya Nakatsura

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Glypican-3 (GPC3) is useful not only as a novel tumor marker, but also as an oncofetal antigen for immunotherapy. We recently established HLA-A2-restricted GPC3144-152 peptide-specific CTL clones from hepatocellular carcinoma patients after GPC3144-152 peptide vaccination. The present study was designed to evaluate the tumor reactivity of a HLA-A2-restricted GPC3144-152 peptide-specific CTL clone against ovarian clear cell carcinoma (CCC) cell lines. The GPC3144-152 peptide-specific CTL clone could recognize HLA-A2-positive and GPC3-positive ovarian CCC cell lines on interferon (IFN)-γ enzyme-linked immunospot assay and showed cytotoxicity against KOC-7c cells. The CTL clone recognized naturally processed GPC3-derived peptide on ovarian CCC cells in a HLA class I-restricted manner. Moreover, we confirmed that the level of GPC3 expression was responsible for CTL recognition and that subtoxic-dose chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTL. Thus, it might be possible to treat ovarian CCC patients by combining chemotherapy with immunotherapy. Our data suggest that GPC3 could be an effective target for immunotherapy against ovarian CCC.

Original languageEnglish
Pages (from-to)1622-1629
Number of pages8
JournalCancer science
Volume102
Issue number9
DOIs
Publication statusPublished - 01-09-2011

Fingerprint

Glypicans
Immunotherapy
Carcinoma
Drug Therapy
HLA-A2 Antigen
Clone Cells
Peptides
Enzyme-Linked Immunospot Assay
Cell Line
Tumor Biomarkers
Interferons
Hepatocellular Carcinoma
Neoplasms
Vaccination

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Suzuki, S., Yoshikawa, T., Hirosawa, T., Shibata, K., Kikkawa, F., Akatsuka, Y., & Nakatsura, T. (2011). Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer science, 102(9), 1622-1629. https://doi.org/10.1111/j.1349-7006.2011.02003.x
Suzuki, Shiro ; Yoshikawa, Toshiaki ; Hirosawa, Tomoya ; Shibata, Kiyosumi ; Kikkawa, Fumitaka ; Akatsuka, Yoshiki ; Nakatsura, Tetsuya. / Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. In: Cancer science. 2011 ; Vol. 102, No. 9. pp. 1622-1629.
@article{1f5235f8590645ad9df32f3e8458b754,
title = "Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma",
abstract = "Glypican-3 (GPC3) is useful not only as a novel tumor marker, but also as an oncofetal antigen for immunotherapy. We recently established HLA-A2-restricted GPC3144-152 peptide-specific CTL clones from hepatocellular carcinoma patients after GPC3144-152 peptide vaccination. The present study was designed to evaluate the tumor reactivity of a HLA-A2-restricted GPC3144-152 peptide-specific CTL clone against ovarian clear cell carcinoma (CCC) cell lines. The GPC3144-152 peptide-specific CTL clone could recognize HLA-A2-positive and GPC3-positive ovarian CCC cell lines on interferon (IFN)-γ enzyme-linked immunospot assay and showed cytotoxicity against KOC-7c cells. The CTL clone recognized naturally processed GPC3-derived peptide on ovarian CCC cells in a HLA class I-restricted manner. Moreover, we confirmed that the level of GPC3 expression was responsible for CTL recognition and that subtoxic-dose chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTL. Thus, it might be possible to treat ovarian CCC patients by combining chemotherapy with immunotherapy. Our data suggest that GPC3 could be an effective target for immunotherapy against ovarian CCC.",
author = "Shiro Suzuki and Toshiaki Yoshikawa and Tomoya Hirosawa and Kiyosumi Shibata and Fumitaka Kikkawa and Yoshiki Akatsuka and Tetsuya Nakatsura",
year = "2011",
month = "9",
day = "1",
doi = "10.1111/j.1349-7006.2011.02003.x",
language = "English",
volume = "102",
pages = "1622--1629",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

Suzuki, S, Yoshikawa, T, Hirosawa, T, Shibata, K, Kikkawa, F, Akatsuka, Y & Nakatsura, T 2011, 'Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma', Cancer science, vol. 102, no. 9, pp. 1622-1629. https://doi.org/10.1111/j.1349-7006.2011.02003.x

Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. / Suzuki, Shiro; Yoshikawa, Toshiaki; Hirosawa, Tomoya; Shibata, Kiyosumi; Kikkawa, Fumitaka; Akatsuka, Yoshiki; Nakatsura, Tetsuya.

In: Cancer science, Vol. 102, No. 9, 01.09.2011, p. 1622-1629.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma

AU - Suzuki, Shiro

AU - Yoshikawa, Toshiaki

AU - Hirosawa, Tomoya

AU - Shibata, Kiyosumi

AU - Kikkawa, Fumitaka

AU - Akatsuka, Yoshiki

AU - Nakatsura, Tetsuya

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Glypican-3 (GPC3) is useful not only as a novel tumor marker, but also as an oncofetal antigen for immunotherapy. We recently established HLA-A2-restricted GPC3144-152 peptide-specific CTL clones from hepatocellular carcinoma patients after GPC3144-152 peptide vaccination. The present study was designed to evaluate the tumor reactivity of a HLA-A2-restricted GPC3144-152 peptide-specific CTL clone against ovarian clear cell carcinoma (CCC) cell lines. The GPC3144-152 peptide-specific CTL clone could recognize HLA-A2-positive and GPC3-positive ovarian CCC cell lines on interferon (IFN)-γ enzyme-linked immunospot assay and showed cytotoxicity against KOC-7c cells. The CTL clone recognized naturally processed GPC3-derived peptide on ovarian CCC cells in a HLA class I-restricted manner. Moreover, we confirmed that the level of GPC3 expression was responsible for CTL recognition and that subtoxic-dose chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTL. Thus, it might be possible to treat ovarian CCC patients by combining chemotherapy with immunotherapy. Our data suggest that GPC3 could be an effective target for immunotherapy against ovarian CCC.

AB - Glypican-3 (GPC3) is useful not only as a novel tumor marker, but also as an oncofetal antigen for immunotherapy. We recently established HLA-A2-restricted GPC3144-152 peptide-specific CTL clones from hepatocellular carcinoma patients after GPC3144-152 peptide vaccination. The present study was designed to evaluate the tumor reactivity of a HLA-A2-restricted GPC3144-152 peptide-specific CTL clone against ovarian clear cell carcinoma (CCC) cell lines. The GPC3144-152 peptide-specific CTL clone could recognize HLA-A2-positive and GPC3-positive ovarian CCC cell lines on interferon (IFN)-γ enzyme-linked immunospot assay and showed cytotoxicity against KOC-7c cells. The CTL clone recognized naturally processed GPC3-derived peptide on ovarian CCC cells in a HLA class I-restricted manner. Moreover, we confirmed that the level of GPC3 expression was responsible for CTL recognition and that subtoxic-dose chemotherapy made tumor cells more susceptible to the cytotoxic effect of CTL. Thus, it might be possible to treat ovarian CCC patients by combining chemotherapy with immunotherapy. Our data suggest that GPC3 could be an effective target for immunotherapy against ovarian CCC.

UR - http://www.scopus.com/inward/record.url?scp=80051824942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051824942&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2011.02003.x

DO - 10.1111/j.1349-7006.2011.02003.x

M3 - Article

C2 - 21668581

AN - SCOPUS:80051824942

VL - 102

SP - 1622

EP - 1629

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -